Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-1801
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer ; volume:3 ; number:1 ; day:22 ; month:2 ; year:2014 ; pages:1-7 ; date:12.2014
SpringerPlus ; 3, Heft 1 (22.2.2014), 1-7, 12.2014
- Urheber
-
Chew, Helen Kent
- Beteiligte Personen und Organisationen
-
Schwartzberg, Lee
Badarinath, Suprith
Rubin, Peter
Shumaker, Grace
Daugherty, James
DeSilvio, Michelle
Mahoney, Janine
SpringerLink (Online service)
- DOI
-
10.1186/2193-1801-3-108
- URN
-
urn:nbn:de:1111-201606107857
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chew, Helen Kent
- Schwartzberg, Lee
- Badarinath, Suprith
- Rubin, Peter
- Shumaker, Grace
- Daugherty, James
- DeSilvio, Michelle
- Mahoney, Janine
- SpringerLink (Online service)
Ähnliche Objekte (12)
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
Recombinant monoclonal antibody trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2-neu proto-oncogene : a systematic review
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer
Inhibiting HER3 Hyperphosphorylation in HER2‐Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
Recombinant monoclonal antibody trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2-neu proto-oncogene : a systematic review
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer
Inhibiting HER3 Hyperphosphorylation in HER2‐Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
Recombinant monoclonal antibody trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2-neu proto-oncogene : a systematic review
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer
Inhibiting HER3 Hyperphosphorylation in HER2‐Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC